Division on Substance Use Disorders, New York State Psychiatric Institute, New York, New York.
Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
Am J Addict. 2020 Jul;29(4):345-348. doi: 10.1111/ajad.13018. Epub 2020 Mar 13.
Highly potent synthetic opioids (HPSO) are increasingly responsible for opioid overdose deaths in the United States.
In an open-label, uncontrolled trial to test the feasibility of extended-release buprenorphine (BXR) injection treatment of heroin-using individuals with opioid use disorder testing positive for HPSO, participants were enrolled and began an induction with sublingual BXR (n = 5). During the induction, ancillary medications (clonidine, clonazepam, zolpidem, and prochlorperazine) were provided for breakthrough opioid withdrawal symptoms.
Two participants received the BXR injection on the second day of the induction and three participants on the third day.
All five participants were retained at least 1-month postinduction.
It may be feasible to provide BXR treatment to HPSO-positive heroin users rapidly to achieve clinical stabilization. (Am J Addict 2020;00:00-00).
在美国，高活性合成阿片类药物（HPSO）越来越多地导致阿片类药物过量死亡。
在一项开放性、非对照试验中，我们测试了使用经 HPSO 检测呈阳性的海洛因使用者的延长释放丁丙诺啡（BXR）注射治疗的可行性，招募了参与者并开始使用舌下 BXR 诱导（n=5）。在诱导过程中，提供了辅助药物（可乐定、氯硝西泮、唑吡坦和丙氯拉嗪）来缓解突破性阿片类戒断症状。
两名参与者在诱导的第二天接受了 BXR 注射，三名参与者在第三天接受了 BXR 注射。
所有五名参与者在诱导后至少 1 个月内都被保留下来。
快速向 HPSO 阳性的海洛因使用者提供 BXR 治疗以实现临床稳定可能是可行的。
